Latest news with #Coric
![2025 Western & Southern Open: Coric [92nd] vs. Nava [114th] Prediction, Odds and Match Preview](/_next/image?url=https%3A%2F%2Fwww.gannett-cdn.com%2Fauthoring%2Fimages%2FDataSkriveSportsbookWire%2F2025%2F04%2F16%2FSSBK%2F83116842007-10192539.jpeg%3Fauto%3Dwebp%26crop%3D1199%2C675%2Cx0%2Cy62%26format%3Dpjpg%26width%3D1200&w=3840&q=100)
![2025 Western & Southern Open: Coric [92nd] vs. Nava [114th] Prediction, Odds and Match Preview](/_next/image?url=https%3A%2F%2Fall-logos-bucket.s3.amazonaws.com%2Fusatoday.com.png&w=48&q=75){kind=small}
USA Today
3 days ago
- Sport
- USA Today
2025 Western & Southern Open: Coric [92nd] vs. Nava [114th] Prediction, Odds and Match Preview
On Friday, Borna Coric (No. 92 in the world) faces Emilio Nava (No. 114) in the Round of 128 at the Western & Southern Open. Nava is favored (-200) in this match versus Coric (+154). Interested in this match? Go to Tennis Channel to see it, and for coverage throughout the Western & Southern Open. Tennis odds courtesy of BetMGM Sportsbook. Odds updated Thursday at 6:35 PM ET. For a full list of sports betting odds, access USA TODAY Sports Betting Scores Odds Hub. Borna Coric vs. Emilio Nava matchup info Watch the Tennis Channel and more sports on Fubo! Coric vs. Nava Prediction Based on the implied probility from the moneyline, Coric has a 66.7% to win. Coric vs. Nava Betting Odds Coric vs. Nava matchup performance & stats
Yahoo
4 days ago
- Sport
- Yahoo
Here are the best first-round ATP matches to watch in the Cincinnati Open
After two days of qualifying, the first round of the Cincinnati Open is slated to begin Aug. 7 at the Lindner Family Tennis Center. The ATP main draw took place Aug. 5. Here are the top first-round men's matches to watch while the majority of the world's top players await in the Round of 64. More: Novak Djokovic out of Cincinnati Open for second straight year Will Gael Monfils notch another Cincinnati upset? One year ago, Gael Monfils became the second-oldest player to defeat a top 3 player this century with an upset of Carlos Alcaraz in the Round of 32. Monfils, 38, has reached the Round of 16 in Mason in each of his previous three appearances. Monfils will face Nishesh Basavareddy in the first round. If the veteran can take out the American wild card, Monfils would get a second-round matchup with World No. 3 Alexander Zverev, the 2021 Cincinnati Open champion. Monfils is 3-1 all-time against Zverev, though the two haven't met since 2021 (Indian Wells). More: 'Really special.' Here are the local products to watch in the 2025 Cincinnati Open Americans Tristan Boyer, Brandon Holt square off in Cincinnati Upon the initial release of the main draw, the only matchup featuring two Americans is between wild cards Tristan Boyer and Brandon Holt. Of the 37 nations represented in Mason, the United States has the largest contingent with 24 players. With a combined 3-11 record between them, one will start the Cincinnati Open on the right foot. Holt (0-3) has never won a singles match in an ATP Masters 1000 event, despite playing his way through qualifiers in Cincinnati last year and Miami in March. Boyer won a first-round tilt at Indian Wells in March and is making his Cincinnati debut. Will former Cincinnati open champion Borna Coric face Taylor Fritz? Borna Coric, who pulled off an improbable run to the Cincinnati Open title in 2022, is in danger of slipping out of the top 100 (No. 92). Coric lost in the first round of qualifying last year in Mason and will face Christopher O'Connell in the first round. Should he advance, Coric would set up a matchup with No. 4 Taylor Fritz. Coric is 4-1 all-time vs. Fritz, but the American rolled to a 6-3, 6-2 win over Coric in the United Cup in December. Corentin Moutet begins Cincinnati Open vs. Mackenzie McDonald Fans in Mason may not know much about Corentin Moutet, but they could be educated soon enough. The 26-year-old Frenchman enters Cincinnati with a career-high ranking (No. 46). He has played his way through qualifying three times in Cincinnati but has yet to break through in the main draw (0-3). Moutet is coming off a semifinal run in Washington, a first-round win in Wimbledon and a runner-up finish in an ATP 250 (Mallorca, Spain). He'll face American Mackenzie McDonald, who reached the Cincinnati Open Round of 16 in 2023, in the first round. This article originally appeared on Cincinnati Enquirer: Best ATP matchups in first round of Cincinnati Open
Time of India
20-05-2025
- Sport
- Time of India
Top seed Borna Coric stunned by wildcard Titouan Droguet in French Open qualifier
Droguet's Breakthrough Performance Live Events Wide Open Qualifying Draw (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel There was a dramatic upset on Court Suzanne-Lenglen when top seed Borna Coric was eliminated in the first round of French Open qualifying by French wildcard Titouan Droguet , who won 7-5, 6-7, 7-6 in an engrossing three-set seed Coric, No. 83 and former No. 12 was heavily favored to cruise through qualifying, having met with a 26-8 win-loss record this year and four Challenger titles, two of them on clay. His recent playing record and Grand Slam experience also made him the heavy favorite, but he found it difficult to get his rhythm going against the bold after coming back to win the second set in a tiebreak, Coric was not able to resist the Frenchman's consistent aggression in the deciding set. Ranked No. 232, Droguet kept his cool in front of a raucous home crowd, winning the final set tiebreak and securing a spot in the second Droguet, this win is the largest of his career and a coming-out party on one of tennis's largest stages. The 23-year-old, who had never faced Coric previously, equaled the Croatian in consistency from the baseline and seized upon important moments, especially in the intense third momentum firmly on his side, Droguet will return to the courts on Thursday, May 22, for a second-round qualifying match against fellow Frenchman Arthur Gea . Gea, also a wildcard, advanced after defeating Alexander Blockx in his own opening round. The all-French encounter promises to be a dynamic battle, with both players eyeing a breakthrough at Roland Garros Following the first seed's early elimination, Coric's loss expands the field for the men's qualifiers, creating additional opportunities for other aspirants and lower-seeded players. The surprise serves as a reminder of how difficult and unpredictable Grand Slam qualifying is, with any match having the potential to completely change the course of Score: Titouan Droguet defeated Borna Coric 7-5, 6-7, 7-6
Yahoo
25-04-2025
- Business
- Yahoo
Biohaven stock slides on withdrawal of European marketing application
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Biohaven lost close to $400 million in market value Friday on news that the Connecticut-based drug developer had withdrawn an application to get one of its most advanced experimental therapies approved in Europe. The company first asked the European Medicines Agency for approval in late 2023, believing enough evidence had been gathered to show its drug, tentatively branded as Dazluma, is effective at treating 'spinocerebellar ataxia,' a type of rare genetic disorder that impairs nerve cells. Once in the body, the drug is designed to break down into riluzole, a molecule already approved in Europe and the U.S. for patients with ALS. On Friday, the EMA revealed that Biohaven withdrew its application on March 24. The agency's main drug review committee said, by that time, it had some concerns about Dazluma, and its provisional opinion was a marketing authorization couldn't be granted. The committee explained that not only was Dazluma's effectiveness not proven, but Biohaven had requested the drug receive a 'new active substance' classification, which comes with significant commercial benefits. EMA staff weren't convinced the drug is significantly different than plain riluzole. In an emailed statement, Biohaven CEO Vlad Coric said his company ultimately pulled the approval application once it became clear the committee didn't intend on bestowing that classification. Coric added that Biohaven is committed to quickly providing the committee with either further arguments, 'appropriate data,' or both, and plans to do so in approximately three months. The company 'remains committed to the Dazluma program and plans to resubmit to EMA this year once the data is generated to respond to' the new active substance issue. "In our view, we view this as a speed bump, but not ultimately a roadblock, on the [European approval] front," wrote Charles Duncan, an analyst for Cantor Fitzgerald, in a note to clients. Biohaven shares were down roughly 16% Friday afternoon, to trade around $19.50 apiece. Meanwhile, the company has also submitted an application to the Food and Drug Administration, and an approval verdict is expected sometime between July and the end of September. To Leonid Timashev, an analyst at the investment bank RBC Capital Markets, the withdrawal in Europe adds risk to the U.S. review, as it 'calls into question whether the FDA would be similarly strict.' Biohaven investors have 'been more bearish lately, and questions have focused on what can drive a turnaround in shares,' he wrote in a note to clients. Most believe FDA approval is 'critical to helping the stock recover. We believe this puts additional pressure on the news, and explains the outsized stock move.' In late 2022, Biohaven completed selling off its portfolio of migraine medications to Pfizer for nearly $12 billion. Since then, the new company has been trying to find its next success story, amassing a research pipeline with more than a dozen experimental medicines targeting a range of disease categories, from oncology to immunology to neuroscience. Yet a couple of those medicines recently hit setbacks in clinical testing. Investor confidence in the pipeline seems to have waned over the past year, with Biohaven shares now having lost two-thirds of their value from when they peaked at roughly $58 in March 2024. Recommended Reading After setback, Biohaven to seek approval of neurological disorder drug Sign in to access your portfolio
![2025 Mutua Madrid Open: Arnaldi [44th] vs. Coric [104th] Prediction, Odds and Match Preview](/_next/image?url=https%3A%2F%2Fwww.gannett-cdn.com%2Fauthoring%2Fimages%2FDataSkriveSportsbookWire%2F2025%2F04%2F16%2FSSBK%2F83116869007-14991234.jpeg%3Fauto%3Dwebp%26crop%3D1199%2C676%2Cx0%2Cy73%26format%3Dpjpg%26width%3D1200&w=3840&q=100)
USA Today
23-04-2025
- Sport
- USA Today
2025 Mutua Madrid Open: Arnaldi [44th] vs. Coric [104th] Prediction, Odds and Match Preview
2025 Mutua Madrid Open: Arnaldi [44th] vs. Coric [104th] Prediction, Odds and Match Preview Matteo Arnaldi (No. 44 ranking) will take on Borna Coric (No. 104) in the Round of 128 of the Mutua Madrid Open on Thursday, April 24. Arnaldi is the favorite (-175) in this match against the underdog Coric (+135). Tennis odds courtesy of BetMGM Sportsbook. Odds updated Wednesday at 2:35 AM ET. For a full list of sports betting odds, access USA TODAY Sports Betting Scores Odds Hub. Matteo Arnaldi vs. Borna Coric matchup info Tournament: Mutua Madrid Open Mutua Madrid Open Round: Round of 128 Round of 128 Date: Thursday, April 24 Thursday, April 24 Court Surface: Clay Watch the Tennis Channel and more sports on Fubo! Arnaldi vs. Coric Prediction Based on the implied probility from the moneyline, Arnaldi has a 63.6% to win. Arnaldi vs. Coric Betting Odds Arnaldi vs. Coric matchup performance & stats
